Ji-Ping HOU, Xue-Bo MEN, Lian-Ying YANG, En-Kun HAN, Chun-Qi HAN, Li-Bin LİU

CircCCT3 Acts as a Sponge of miR-613 to Promote Tumor Growth of Pancreatic Cancer Through Regulating VEGFA/VEGFR2 Signaling

Background: Circular RNAs (CircRNAs) have been recently implicated in the progression of pancreatic cancer (PC). Aims: To investigate the involvement of CircCCT3 in PC and studying its interactions and functioning during the progression of PC in vitro and in vivo, using methods of molecular biology and bioinformatics. Study Design: Experimental study. Methods: The expressions of CircCCT3 and miR-613 in pancreatic carcinoma tissues and cell lines were evaluated by quantitative real-time polymerase chain reaction (PCR). The relationship between clinical pathologic features as well as the survival rate and CircCCT3 expression was analyzed with chi-square test and the Kaplan–Meier method. CCK-8, wound healing, transwell assays, and the fluorescein isothiocyanate- AnnexinV/propidium iodide (FITC-AnnexinV/PI) assay were used to assess cell proliferation, migration, invasion, and apoptosis after CircCCT3 overexpression or downregulation. The Dual- Luciferase reporter assay, RNA immunoprecipitation (RIP), RNA pull-down and fluorescence in situ hybridization (FISH) assays were performed to validate the potential interaction of CircCCT3, miR-613, and vascular endothelial growth factor (VEGFA). The nude mouse xenograft tumor assay was used to detect CircCCT3 effects on pancreatic tumorigenesis in vivo. Western blotting analysis was performed to examine the VEGFA and the vascular endothelial growth factor receptor 2 (VEGFR2) protein expressions following. Results: CircCCT3 expression was significantly increased in PC tissues (3.41 ± 0.57 vs. 1.00 ± 0.10, P < .01) and cell lines (Patu8988 2.57 ± 0.20; SW1990 2.88 ± 0.10; BxPC-3 2.45 ± 0.20; Panc02 2.99 ± 0.10 vs. H6c7 1.00 ± 0.10; all P < .001). CircCCT3 expression was negatively correlated with miR-613 expression. PC patients with high CircCCT3 expression exhibited significantly poorer overall survival rate than those patients with low CircCCT3 expression (P = .013). Moreover, it was found that CircCCT3 promoted cell proliferation, migration, and invasion, and inhibited cell apoptosis in PC cells. The CircCCT3 acted as a sponge for the miR-613 to facilitate VEGFA and VEGFR2 expression. si-CirCCT3 also inhibited tumor growth of PC in nude mice. si-CircCCT3 reduced VEGFA and VEGFR2 expression, whereas overexpression of CircCCT3 increased VEGFA and VEGFR2 expression. Conclusion: Increased CircCCT3 suggests a poor prognosis for PC patients and promotes the migration and invasion through targeting VEGFA/VEGFR2 signaling. CircCCT3 may serve as a potential and promising therapeutic target for PC treatment.

PDF

___

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7-34. [CrossRef]
2. Rahib L, Smith BD, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913-2921. [CrossRef]
3. Clerget G, Abel Y, Rederstorff M. Small non-coding RNAs: a quick look in the rearview mirror.Methods Mol Biol. 2015;1296:3-9. [CrossRef]
4. Wei JW, Huang K, Yang C, Kang CS. Non-coding RNAs as regulators in epigenetics (Review) [review]. Oncol Rep. 2017;37(1):3-9. [CrossRef]
5. Toden S, Zumwalt TJ, Goel A. Non-coding RNAs and potential therapeutic targeting in cancer.Biochim Biophys Acta Rev Cancer. 2021;1875(1):188491. [CrossRef]
6. Romano G, Veneziano D, Acunzo M, Croce CM. Small non-coding RNA and cancer. Carcinogenesis. 2017;38(5):485-491. [CrossRef]
7. Chen LL,Yang L. Regulation of circRNA biogenesis.RNA Biol. 2015;12(4):381-388. [CrossRef]
8. Meng S, Zhou H, Feng Z, et al. CircRNA: functions and properties of a novel potential biomarker for cancer. Mol Cancer. 2017;16(1):94. [CrossRef]
9. Rong D, Sun H, Li Z, et al. An emerging function of circRNA-miRNAs-mRNA axis in human diseases .Oncotarget. 2017;8(42):73271-73281. [CrossRef]
10. Yin Y, Long J, He Q, et al. Emerging roles of circRNA in formation and progression of cancer.J Cancer. 2019;10(21):5015-5021. [CrossRef]
11. Lv B, Zhu W, Feng C. Coptisine blocks secretion of exosomal CircCCT3 from cancer- associated fibroblasts to reprogram glucose metabolism in hepatocellular carcinoma.DNA Cell Biol. 2020. [CrossRef]
12. Li W, Xu Y, Wang X, et al. CircCCT3 modulates vascular endothelial growth factor A and Wnt signaling to enhance colorectal cancer metastasis Through sponging miR- 613. DNA Cell Biol. 2020;39(1):118-125. [CrossRef]
13. Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017;16(3):203-222. [CrossRef]
14. Treiber T, Treiber N, Meister G. Regulation of microRNA biogenesis and its crosstalk with other cellular pathways. Nat Rev Mol Cell Biol. 2019;20(1):5-20. [CrossRef]
15. Song H, Nan Y, Wang X, et al. MicroRNA-613 inhibits proliferation and invasion of renal cell carcinoma cells through targeting FZD7. Mol Med Rep. 2017;16(4):4279- 4286. [CrossRef]
16. Yu X, Wang W. Tumor suppressor microRNA-613 inhibits glioma cell proliferation, invasion and angiogenesis by targeting vascular endothelial growth factor A. Mol Med Rep. 2017;16(5):6729-6735. [CrossRef]
17. Liu C,Jiang Y,Han B. miR-613 suppresses chemoresistance and stemness in triplenegative breast cancer by targeting FAM83A.Cancer Manag Res. 2020;12:12623- 12633. [CrossRef]
18. Ji H,Hu NJ. MiR-613 blocked the progression of cervical cancer by targeting LETM1. Eur Rev Med Pharmacol Sci. 2020;24(12):6576-6582. [CrossRef]
19. Sargent KM, Clopton DT, Lu N, Pohlmeier WE, Cupp AS. VEGFA splicing: divergent isoforms regulate spermatogonial stem cell maintenance. Cell Tissue Res. 2016;363(1):31-45. [CrossRef]
20. Reinmuth N, Parikh AA, Ahmad SA, et al. Biology of angiogenesis in tumors of the gastrointestinal tract. Microsc Res Tech. 2003;60(2):199-207. [CrossRef]
21. Itakura J, Ishiwata T, Shen B, Kornmann M, Korc M. Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer. Int J Cancer. 2000;85(1):27-34. [CrossRef]
22. Seo Y, Baba H, Fukuda T, Takashima M, Sugimachi K. High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer. 2000;88(10):2239-2245. [CrossRef]
23. Zhong Z, Huang M, Lv M, et al. Circular RNA MYLK as a competing endogenous RNA promotes bladder cancer progression through modulating VEGFA/VEGFR2 signaling pathway. Cancer Lett. 2017;403:305-317. [CrossRef]
24. Zhang Q, Lu S, Li T et al. ACE2 inhibits breast cancer angiogenesis via suppressing the VEGFa/VEGFR2/ERK pathway. J Exp Clin Cancer Res. 2019;38(1):173. [CrossRef]
25. Noh JH, Kim KM, McClusky WG, Abdelmohsen K, Gorospe M. Cytoplasmic functions of long noncoding RNAs. Wiley Interdiscip Rev RNA. 2018;9(3):e1471. [CrossRef]
26. Salzman J, Gawad C, Wang PL, Lacayo N, Brown PO. Circular RNAs are the predominant transcript isoform from hundreds of human genes in diverse cell types. PLOS ONE. 2012;7(2):e30733. [CrossRef]
27. Liu J, Liu T, Wang X, He A. Circles reshaping the RNA world: from waste to treasure. Mol Cancer. 2017;16(1):58. [CrossRef]
28. Rong Z, Xu J, Shi S, et al. Circular RNA in pancreatic cancer: a novel avenue for the roles of diagnosis and treatment. Theranostics. 2021;11(6):2755-2769. [CrossRef]
29. Huang L, Han J, Yu H, et al. CircRNA_000864 Upregulates B-cell Translocation Gene 2 Expression and Represses Migration and Invasion in Pancreatic Cancer Cells by Binding to miR-361-3p. Front Oncol. 2020;10:547942. [CrossRef]
30. Ye Z, Zhu Z, Xie J, et al. Hsa_circ_0000069 Knockdown Inhibits tumorigenesis and exosomes with Downregulated hsa_circ_0000069 Suppress Malignant Transformation via Inhibition of STIL in Pancreatic Cancer. Int J Nanomedicine. 2020;15:9859- 9873. [CrossRef]
31. Zhang X, Tan P, Zhuang Y, Du L. hsa_circRNA_001587 upregulates SLC4A4 expression to inhibit migration, invasion, and angiogenesis of pancreatic cancer cells via binding to microRNA-223. Am J Physiol Gastrointest Liver Physiol. 2020;319(6):G703-G717. [CrossRef]
32. Kong Y, Li Y, Luo Y, et al. circNFIB1 inhibits lymphangiogenesis and lymphatic metastasis via the miR-486-5p/PIK3R1/VEGF-C axis in pancreatic cancer. Mol Cancer. 2020;19(1):82. [CrossRef]
33. Claesson-Welsh L,Welsh M.VEGFA and tumour angiogenesis. J Intern Med. 2013;273(2):114-127. [CrossRef]
34. Wang Y, Zhang F, Wang J, et al. lncRNA LOC100132354 promotes angiogenesis through VEGFA/VEGFR2 signaling pathway in lung adenocarcinoma. Cancer Manag Res. 2018;10:4257-4266. [CrossRef]
34. Mastrella G, Hou M, Li M, et al. Targeting APLN/APLNR improves antiangiogenic efficiency and blunts proinvasive side effects of VEGFA/VEGFR2 blockade in glioblastoma. Cancer Res. 2019;79(9):2298-2313. [CrossRef]
35. Fontanella C, Ongaro E, Bolzonello S, et al. Clinical advances in the development of novel VEGFR2 inhibitors. Ann Transl Med. 2014;2(12):123. [CrossRef]
36. Lin W, Zhang T, Ding G, et al. Circular RNA circCCT3 promotes hepatocellular carcinoma progression by regulating the miR12875p/TEAD1/PTCH1/LOX axis. Mol Med Rep. 2021;23(5):375. [CrossRef]